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Objectives. To investigate the effect of endothelial dysfunction on development of cardiac 
hypertrophy and fibrosis.  
Background. Endothelial dysfunction accompanies cardiac hypertrophy and fibrosis but its 
contribution to these conditions is unclear. Increased NADPH oxidase-2 (NOX2) activation 
causes endothelial dysfunction.  
Methods. Transgenic mice with endothelial-specific NOX2 overexpression (TG) and wild-
type littermates received chronic AngII infusion (1.1mg/kg/day, 2 weeks) to induce 
hypertrophy and fibrosis.  
Results. TG had similar systolic hypertension and hypertrophy to wild-type but developed 
greater cardiac fibrosis and evidence of isolated left ventricular diastolic dysfunction 
(P<0.05). TG myocardium had more inflammatory cells and VCAM-1-positive vessels than 
wild-type after AngII (both P<0.05). TG microvascular endothelial cells (EC) treated with 
AngII recruited 2-fold more leukocytes than wild-type in an in vitro adhesion assay (P<0.05). 
However, inflammatory cell NOX2 per se was not essential for the pro-fibrotic effects of 
AngII. TG mice showed a higher level of endothelial-mesenchymal transition (EMT) than 
wild-type after AngII infusion. In cultured EC treated with AngII, NOX2 enhanced EMT as 
assessed by the relative expression of fibroblast versus endothelial-specific markers.  
Conclusion. AngII-induced endothelial NOX2 activation has profound pro-fibrotic effects in 
the heart in vivo, leading to a diastolic dysfunction phenotype. Endothelial NOX2 enhances 
EMT and has pro-inflammatory effects. This may be an important mechanism underlying 
cardiac fibrosis and diastolic dysfunction during increased renin-angiotensin activation.  
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Endothelial dysfunction accompanies conditions such as hypertension that predispose to 
adverse cardiac remodeling, and predicts future cardiovascular morbidity.(1) As well as 
modulating vascular function, the endothelium has direct effects on cardiac function.(2-4) 
Pioneering work by Brutsaert and colleagues(3) demonstrated that cardiac endothelial cells 
directly influence myocardial contraction, a concept later confirmed in humans in vivo.(5) 
The importance of endothelial-cardiomyocyte crosstalk has been demonstrated in several 
disease settings.(3,6) However, the role of endothelial dysfunction in the pathogenesis of 
adverse cardiac remodeling caused by increased renin-angiotensin activation remains unclear. 
 A major driver of endothelial dysfunction is the reactive oxygen species (ROS)-
generating enzyme, NADPH oxidase-2 (NOX2), which is activated by angiotensin II (AngII) 
and other agonists.(7) NOX2 is expressed in endothelium as well as cardiomyocytes, 
adventitial fibroblasts, inflammatory cells and conduit vascular smooth muscle cells. 
Vascular NOX2 expression and activity are increased in hypertension where it modulates 
intracellular signaling pathways that promote vascular remodeling, contributes to vasodilator 
dysfunction through superoxide-mediated inactivation of nitric oxide, and may have pro-
inflammatory effects.(7)  
 To investigate the pathophysiologic roles of endothelial NOX2, we generated a 
transgenic mouse model with endothelial-specific NOX2 overexpression.(8) This model has a 
2-fold increase in endothelial NOX2 protein levels and displays augmented NOX2 activation 
in response to AngII. Here, we used this model to investigate the effects of endothelial NOX2 
activation on the development of cardiac hypertrophy, fibrosis and dysfunction during 
chronic AngII elevation.  
METHODS 
Detailed methods are provided in the online supplement. 
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Animal experiments complied with UK Home Office regulations. Male transgenic mice with 
endothelium-targeted NOX2 overexpression (TG) (8) were compared with wild-type 
littermates. Chimeric mice were generated by bone marrow (BM) transplantation.(9) AngII 
(1.1mg/kg/day) or vehicle were infused via osmotic minipumps. Blood pressure was 
measured by radiotelemetry or tail-cuff plethysmography.(10) Left ventricular pressure-
volume relations and echocardiography were performed as described.(11) Cardiac fibrosis 
was quantified in Picrosirius Red-stained paraffin sections while immunostaining was 
performed in cryosections. LV homogenate NADPH oxidase activity was measured using 
lucigenin-enhanced chemiluminescence.(12)  
 In vitro leukocyte adhesion to coronary microvascular endothelial cells (CMEC) from 
TG or wild-type mouse hearts was studied in a flow chamber,(13) with or without AngII 
(0.1µmol/L, 4h). To assess endothelial-mesenchymal transition (EMT), cultured human aortic 
EC were infected with Ad.βGal or Ad.NOX2 virus, then treated with 0.1µmol/L AngII or 
vehicle for up to 5 days. Co-culture experiments with EC and fibroblasts were performed in 
Transwell dishes. 
 Data are expressed as mean±SEM. Comparisons were made by repeated measures 
ANOVA, 2-way ANOVA with Bonferroni post-hoc testing, 1-way ANOVA or Student’s t-
test as appropriate. P<0.05 was considered significant. 
RESULTS  
Effects of endothelial NOX2 overexpression on AngII-induced hypertension and cardiac 
hypertrophy.  
Chronic AngII infusion for 14 days caused similar systolic hypertension in TG and wild-type 
mice (Supplementary Fig. 1A). Left ventricular NADPH oxidase activity increased in both 
AngII-treated groups, with a significantly greater rise in TG (Supplementary Fig. 1B, 
supplementary Fig. 2). AngII infusion induced a similar increase in left ventricle/body weight 
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ratio or cardiomyocyte cross-sectional area in TG and wild-type mice (Supplementary Fig. 
1C,D).   
Endothelial NOX2 overexpression potentiates AngII-induced cardiac fibrosis. 
The extent of AngII-induced fibrosis was significantly (~2-fold) greater in TG than wild-type 
hearts (Supplementary Fig. 1E).  TG also had significantly higher pro-collagen I mRNA 
expression than wild-type (Supplementary Fig. 1F). Representative examples of the fibrosis 
and myocyte hypertrophy are shown in Fig. 1.   
LV diastolic dysfunction with preserved systolic function in endothelial NOX2 TG.  
TG had significantly lower echocardiographic left ventricular end-diastolic dimensions than 
wild-type after chronic AngII infusion (Supplementary Fig. 3). However, there were no 
significant differences in indices such as interventricular septal thickness or ejection fraction. 
More detailed assessment was undertaken by pressure-volume analysis. Systolic function 
assessed by end-systolic elastance or LV dP/dtmax/EDV was similar in AngII-treated wild-
type and TG groups (Supplementary Fig. 4A,B). Left ventricular end-diastolic volume 
increased in wild-type mice after AngII but decreased in TG (Supplementary Fig. 4C). Left 
ventricular end-systolic volume tended to increase in wild-type after AngII treatment but fell 
significantly in TG (Supplementary Fig. 4D). As a result, both stroke volume and stroke work 
were significantly lower in AngII-treated TG versus wild-type (Supplementary Fig. 4E, Table 
1). Isovolumic left ventricular relaxation time-constant and left ventricular end-diastolic 
pressure were similar in wild-type and TG groups (Table 1). However, left ventricular 
diastolic stiffness assessed by the end-diastolic pressure volume relationship was significantly 
higher in AngII-treated TG versus wild-type hearts (Supplementary Fig. 4F). Although there 
was no difference in systolic BP, arterial elastance was significantly higher in AngII-treated 
TG (Table 1). Supplementary Fig. 4G,H show representative steady-state pressure-volume 
loops and the response to preload reduction in wild-type and TG. These indicate that TG 
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hearts were smaller and stiffer than wild-type after chronic AngII, indicating a phenotype of 
isolated diastolic left ventricular dysfunction with preserved systolic function.          
Endothelial NOX2 enhances myocardial inflammatory cell infiltration. 
To investigate mechanisms underlying the increased fibrosis in TG, we assessed myocardial 
inflammatory cell infiltration. TG hearts had significantly more CD45+ inflammatory cells 
and Mac3+ cells (macrophages) after AngII infusion than wild-type (Fig. 2, Supplementary 
Fig. 5). AngII treatment increased connective tissue growth factor and osteopontin mRNA 
levels but levels were similar in wild-type and TG (Supplementary Fig. 6). There was no 
difference between groups in TGFβ, TNFα , MCP-1 or endothelin-1 mRNA levels.   
 To confirm that the effects of endothelial NOX2 on inflammatory infiltration and 
fibrosis were ROS-dependent, mice were treated with the antioxidant N-acetylcysteine 
concurrent with AngII infusion. BP and cardiac hypertrophy were similar in wild-type and 
TG treated with N-acetylcysteine (Supplementary Fig. 7). N-acetylcysteine markedly reduced 
CD45+ cell number in both wild-type and TG AngII-treated groups, and prevented the 
development of fibrosis (Supplementary Fig. 7).   
NOX2 enhances endothelial activation and leukocyte-endothelial interaction. 
We assessed the interaction between inflammatory cells and NOX2-overexpressing 
endothelial cells in an in vitro adhesion assay under flow conditions. Leukocyte attachment to 
TG and wild-type CMEC was low at baseline, but after AngII treatment (0.1 µM, 4 h) 
significantly more leukocytes attached to TG CMEC (Fig. 2C). TG CMEC had significantly 
higher vascular cell adhesion molecule-1 (VCAM-1) protein expression than wild-type after 
AngII treatment (Fig. 2D). In line with this, LV sections of TG treated with chronic AngII 
had more VCAM-1 positive blood vessels than wild-type (Fig. 2E, Supplementary Fig. 8).  
There was no difference in capillary density between TG and wild-type hearts (Fig. 2F).    
Inflammatory cell NOX2 is not essential for AngII-induced cardiac fibrosis.  
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Since NOX2 is abundantly expressed in inflammatory cells, we investigated whether NOX2 
in these cells was required for the pro-fibrotic response to AngII. We used BM 
transplantation to create chimeric mice with different NOX2 genotypes in BM and resident 
tissue cells: (a) wild-type recipient mice with wild-type BM (WT:WT); (b) wild-type 
recipients with BM from global NOX2 knockout mice (KO:WT); (c) global NOX2 knockout 
mice with wild-type BM (WT:KO); (d) NOX2 TG with TG BM (TG:TG); (e) NOX2 TG 
with wild-type BM (WT:TG); and (f) wild-type mice with TG BM (TG:WT). Successful 
alteration of NOX2 genotype after BM transplantation was confirmed by assessing ROS 
production in recipient BM and peripheral blood mononuclear cells (Supplementary Fig. 9A).   
 AngII infusion caused similar increases in BP and hypertrophy among groups 
(Supplementary Fig. 9B,C). AngII-stimulated cardiac fibrosis was significantly lower in 
global NOX2 KO versus wild-type, as reported previously(12) (Supplementary Fig. 10). 
WT:WT and KO:WT mice both had similar fibrosis to un-transplanted wild-type mice 
(Supplementary Fig. 10A,B). In contrast, WT:KO mice had significantly less fibrosis, similar 
to un-transplanted knockout mice (Supplementary Fig. 10A,B). Thus, knockout BM cells did 
not significantly alter AngII-induced fibrosis. Fibrosis in NOX2 TG:TG was similar to that in 
WT:TG while transplantation of TG BM to wild-type mice did not increase the level of 
fibrosis to that in the TG:TG group (Supplementary Fig. 10A right-hand panels, 
Supplementary Fig. 10B). Thus, TG BM cells did not significantly alter AngII-induced 
fibrosis. Taken together, these results indicate that NOX2 in BM cells is dispensable for the 
pro-fibrotic effects of AngII and it is NOX2 in the resident tissue cells that is essential. 
Furthermore, endothelium-targeted NOX2 overexpression does not significantly alter the 
effects of BM cells as compared to wild-type.   
NOX2 promotes endothelial-mesenchymal transition (EMT).  
8 
 
Recent studies indicate that EMT is an important contributor to cardiac fibrosis during 
chronic pressure overload.(14) We therefore investigated whether enhancing NOX2 activity 
in endothelial cells affected EMT. Hearts of AngII-treated TG had significantly higher levels 
of fibroblast-specific α -smooth muscle actin (α SMA) and collagen-1 than wild-type while 
levels of endothelial-specific CD31 were significantly lower (Fig. 3A). Myocardial sections 
of AngII-treated TG showed increased evidence of EMT, as indicated by co-localization of 
endothelial-specific and mesenchymal markers, compared with wild-type (Fig. 3B).  
 To further assess the effects of endothelial NOX2, we studied cultured human aortic 
EC with adenoviral-mediated overexpression of NOX2 or β -galactosidase control, and 
treated with AngII. AngII caused a modest increase in fibroblast-specific markers (FSP-1, α 
SMA) and a concomitant decrease in endothelial-specific markers (CD31, CD144) in control 
EC. This transition from endothelial- to fibroblast-specific expression was enhanced in 
NOX2-overexpressing cells (Fig. 4). NOX2 overxpression per se caused a small switch from 
endothelial to fibroblast-specific expression in the absence of AngII. Supplementary Fig. 11A 
shows representative examples of co-expression of endothelial-specific and mesenchymal 
markers in NOX2-overexpressing cells after AngII. Cellular morphology was significantly 
different after 5 days of AngII treatment, with NOX2-overexpressing cells showing a more 
elongated fibroblast phenotype (Supplementary Fig. 11B).  
Paracrine effects of endothelial cells on fibroblasts? 
It is feasible that NOX2 elevation in EC affects fibroblasts through the direct effects of ROS 
or other released factors. To assess this possibility, we performed experiments in which 
human aortic EC overexpressing NOX2 or β -galactosidase were co-cultured with fibroblasts 
(see Supplementary Methods). Experiments were performed with and without AngII. No 
difference was found between groups in the fibroblast expression of pro-collagen I mRNA or 




We investigated the specific effects of endothelial NOX2 activation on AngII-induced 
cardiac remodeling, taking advantage of a recently developed mouse model with 
endothelium-targeted overexpression of NOX2.(8) The 2-fold increase in endothelial NOX2 
protein in this model has no basal effects but enhances AngII-stimulated increases in NOX2 
activity. In the present study, we found that in vivo AngII-induced endothelial NOX2 
activation (a) enhances the development of cardiac fibrosis independent of cardiomyocyte 
hypertrophy, and leads to a phenotype of left ventricular diastolic dysfunction with preserved 
systolic function; (b) promotes myocardial inflammatory cell infiltration through increased 
endothelial expression of VCAM-1 (i.e. endothelial activation), although NOX2 in 
inflammatory cells is dispensable for the pro-fibrotic effects; (c) enhances EMT which 
contributes to the cardiac fibrosis. Collectively, these data suggest that NOX2-driven 
endothelial dysfunction and activation may be an important mechanism that promotes cardiac 
fibrosis and left ventricular diastolic dysfunction in pathologic settings of renin-angiotensin 
system activation.   
Endothelium-cardiomyocyte crosstalk 
 The cardiac endothelium forms a strategic interface between circulating blood and 
myocardial tissue. Crosstalk between cardiac EC and cardiomyocytes plays important roles in 
normal cardiac development.(3,4) The cardiac endothelium also influences contractile 
function in the adult heart, for example through paracrine factors such as nitric oxide and 
endothelin.(2) Reciprocal signaling between cardiomyocytes and the myocardial 
microvasculature has been found to be important during chronic pressure overload. For 
example, signaling from EC to cardiomyocytes through the neuregulin 1-ErbB2 axis 
promotes cardiomyocyte survival during pressure overload,(15) and angiogenic factors 
released by cardiomyocytes in the chronically overloaded heart regulate myocardial capillary 
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density.(11,16) While these studies support the potential for endothelial dysfunction to affect 
cardiomyocyte growth, survival and contractile function, the effects on cardiac fibrosis in the 
heart under stress are unclear.  
Pro-inflammatory effects of endothelial NOX2 
 Here, we demonstrate that endothelial dysfunction has a profound ROS-dependent 
impact on the development of cardiac fibrosis, independent of cardiomyocyte hypertrophy. 
One mechanism underlying these effects may be the pro-inflammatory properties of activated 
endothelium. The healthy endothelium is anti-inflammatory and anti-thrombotic but in 
pathologic settings such as renin-angiotensin system activation, it becomes activated and 
promotes increased interaction with circulating inflammatory cells.(17) Previous studies 
suggested that NOX2 is involved in cytokine- and AngII-induced EC activation and the 
expression of adhesion molecules such as VCAM-1,(18,19) and in enhanced monocyte 
binding to ECs under oscillatory shear stress.(20) Here, we found that NOX2-overexpressing 
CMEC had a larger increase in VCAM-1 expression after AngII stimulation than wild-type, 
which was associated with greater endothelial-leukocyte adhesion in an in vitro flow assay. 
Consistent with a similar pro-inflammatory action in vivo, TG myocardium had more 
VCAM-1-positive blood vessels and inflammatory cells after AngII treatment than wild-type. 
These results clearly indicate that AngII-induced endothelial NOX2 activation augments an 
inflammatory response in the heart in vivo.  Whether other cell types (e.g. vascular smooth 
muscle cells, pericytes) are also involved is an interesting question. 
 In addition to EC, NOX2 is abundant in inflammatory cells where it is suggested to 
contribute to oxidative stress, for example in atherosclerosis.(21) NOX2 activation in 
inflammatory cells is involved in AngII-induced vascular hypertrophy.(22) It was therefore 
possible that NOX2 activation in infiltrating inflammatory cells (as well as the endothelium) 
might be important in the development of cardiac fibrosis. To dissect the specific contribution 
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of inflammatory cell NOX2 activation, we generated chimeric mice in which the BM 
comprised NOX2-competent or -deficient cells. These series of studies demonstrated that 
NOX2 activation in infiltrating inflammatory cells is dispensable for the development of 
AngII-induced fibrosis and that it is NOX2 in recipient heart cells that is essential for the pro-
fibrotic effects. This result suggests that although NOX2 may be important for certain 
functions of inflammatory cells (e.g. phagocytosis, LDL oxidation in atherosclerosis [21]), it 
is not essential for all functions and is dispensable in the setting of AngII-induced cardiac 
pathology. 
Role of EMT 
 Another mechanism by which endothelial dysfunction might promote cardiac fibrosis 
is through EMT. The transition of epithelial and endothelial cells to a mesenchymal 
phenotype is well recognized to be important in cardiac development. In a landmark study, 
Zeissberg et al.(14) showed that EMT makes a significant contribution to pathologic cardiac 
fibrosis during chronic pressure overload. EC production of endothelin-1 has been reported to 
contribute to EMT in the diabetic heart.(23) We therefore investigated whether endothelial 
NOX2 activation affects EMT. We found evidence of significantly increased EMT in TG 
hearts after chronic AngII as compared with wild-type. More definitive evidence that 
endothelial NOX2 promotes EMT was obtained in cultured EC where NOX2 significantly 
enhanced the transition from endothelial to fibroblast phenotype after AngII treatment. These 
results strongly suggest that NOX2-dependent increase in EMT may be a crucial mechanism 
that enhances cardiac fibrosis in response to chronic AngII treatment. 
 We also tested the possibility that paracrine effects of EC on fibroblasts, for example 
through the direct effects of ROS released by EC, may contribute to fibrosis. In vitro co-
culture experiments with EC and fibroblasts did not provide evidence in support of this 
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possibility. However, a possible contribution of such a mechanism in vivo cannot be 
excluded.   
Isolated diastolic dysfunction 
 A striking functional consequence of endothelial NOX2 overexpression on the 
response to chronically elevated AngII was a phenotype of LV diastolic dysfunction with 
preserved systolic function, resulting in smaller and stiffer hearts and reduced stroke volumes 
in TG compared with wild-type. This was documented in TG by the gold-standard method of 
in vivo pressure-volume analysis, which demonstrated significantly increased left ventricular 
diastolic passive stiffness in the AngII-treated TG versus wild-type group whereas load-
independent indices of systolic function were similar in the two groups. We found no 
significant difference between the groups in parameters of active left ventricular relaxation 
(e.g. the isovolumic relaxation time-constant), suggesting that cardiomyocyte relaxation was 
probably similar in the two groups. This contractile dysfunction phenotype is consistent with, 
and fully explainable by, the increased fibrosis observed in TG independent of differences in 
cardiomyocyte hypertrophy. The use of an endothelium-targeted transgenic model allowed us 
to study the role of endothelial dysfunction/activation independent of other changes that 
occur in the remodeling heart during increased renin-angiotensin system activation. As 
mentioned earlier, NOX2 is also expressed in cardiomyocytes and previous studies in 
cultured cells and in vivo models have shown that cardiomyocyte NOX2 activation may 
contribute to the development of AngII-induced cardiac hypertrophy.(12) No difference was 
found in extent of hypertrophy between wild-type and TG in the current study, consistent 
with the fact that NOX2 was overexpressed specifically in EC. Therefore, the phenotype of 
diastolic left ventricular dysfunction with preserved systolic function found in the current 
model was the consequence specifically of endothelial dysfunction/activation.   
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 The clinical syndrome of heart failure with preserved ejection fraction is currently 
receiving significant attention due to the high prevalence of the condition, controversy 
regarding its etiology and pathogenesis, and the lack of effective therapies.(24) Whilst simple 
extrapolations cannot be made from the current study in a murine model to the clinical 
setting, the occurrence of a contractile dysfunction phenotype that apparently closely 
resembles the cardiac dysfunction found in human heart failure with preserved ejection 
fraction is of great interest. It is notable that previous human studies suggested that 
inflammation contributes to enhanced fibrosis in such patients,(25) consistent with the 
findings of increased inflammatory cell infiltration, fibrosis and diastolic dysfunction in our 
study. The current results raise the intriguing possibility that endothelial 
dysfunction/activation and downstream pathways such as inflammation and EMT may be 
important mechanisms contributing to the development of heart failure with preserved 
ejection fraction. If so, this could provide new therapeutic options to tackle this prevalent 
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FIGURE LEGENDS  
 
Figure 1. Representative myocardial sections showing cardiac hypertrophy and fibrosis. 
Top, cardiomyocyte borders outlined using wheat-germ agglutinin. Scale bars 50 µm. 
Bottom, Picrosirius Red-stained sections. Scale bars 100 µm. Sal = saline. 
 
Figure 2. Inflammatory cell infiltration in vivo and endothelial-leukocyte interaction in 
vitro. (A,B) Mean number of CD45+ and Mac3+ cells/field, respectively. (C) Number of 
leukocytes adherent to WT or TG EC with or without AngII treatment (0.1µM, 4 hr) in an in 
vitro assay. (D) VCAM-1 protein levels in WT and TG EC treated with AngII. 
Representative Western blots at the top, mean data below. (E) Number of VCAM-1 positive 
vessels in myocardial sections from WT and TG.   (F) Capillary density in myocardial 
sections from WT and TG (capillaries/mm2).  * P<0.05 by 2-way ANOVA; n=6-8/group. 
 
Figure 3. Enhanced endothelial-mesenchymal transition in AngII-treated TG hearts. 
(A) Representative Western blots and mean data for CD31, smooth muscle actin (SMA) and 
collagen 1 (Coll) levels in cardiac homogenates from AngII-treated WT or TG mice. Actin 
was used as a loading control. *, P<0.05; n=4/group. (B) Myocardial sections co-stained for 
CD31 (red) and SMA (green) and imaged by confocal microscopy. Yellow color indicates 
co-localisation of endothelial and mesenchymal markers. Scale bar 10 µm. Panels to the right 
show pixel-by-pixel fluorescence intensities of the two fluorophores along the line indicated 
in the top panel (TG AngII) and confirm a significant overlapping pattern between CD31 and 
SMA, indicative of endothelial-mesenchymal transition. 
 
Figure 4. Effect of NOX2 on endothelial-mesenchymal transition in cultured endothelial 
cells. (A) Representative Western blots for CD144, CD31, FSP1, smooth muscle actin (SMA) 
and NOX2 levels in EC overexpressing NOX2 or β-gal and treated with AngII (100 nmol/L) 
or vehicle (Con). GAPDH was a loading control. (B) Mean data for CD144 and SMA protein 






Table 1. Cardiac function assessed by LV pressure-volume loops in WT and TG mice. 
  
 WT Saline WT ANGII TG Saline TG ANGII 
Heart rate (bpm) 552±9 509±17 543±14 543±12 
LVEDP (mmHg) 7.5±0.7 5.0±0.8 6.9±1.1 8.1±2.3 
dP/dtmax (mmHg/min) 7804±459 8348±365 7497±529 8098±435 
dP/dtmin (mmHg/min) -6497±406 -6654±417 -6600±544 -6843±604 
Stroke volume (µL) 16.7±0.9 22.8±1.7** 15.4±1 16.3±1.6** 
End systolic volume (µL) 17.8±1.1 21.9±3.6 17.4±1.4 13.7±0.9‡‡ 
End diastolic volume (µL) 29.5±1.7 39.9±3.7** 29.0±1.4 25.3±1.5‡‡‡ 
Ejection fraction (%) 53±1 57±5 52±4 60±4 
Cardiac output (mL/min/g) 105.5±8.1 112.0±11.5 91.2±5.0 82.3±8.2‡ 
Stroke work (mmHg.µl/g) 14472±1280 17216±1888 12365±865 11569±1324‡ 
Ea (mmHg/µL) 5.7±0.2 4.6±0.4 5.9±0.4 7.0±1.0‡‡ 
Tau-Weiss (ms) 7.4±0.4 6.2±0.6 7.4±0.7 7.8±1.2 
dP/dtmax/EDV 261.9±39.6 258.8±32.0 273.9±73.0 334.8±71.1 
Ees 4.28±0.38 8.91±0.69*** 4.78±0.40 8.91±1.28*** 
EDPVR 0.22±0.03 0.25±0.04 0.20±0.02 0.46±0.11** ‡
Number 10 10 9 8 
Ea, arterial elastance; EDV, end-diastolic volume; Ees, end-systolic elastance; EDPVR, end-
diastolic pressure volume relation.  **,*** = P<0.01, 0.001 respectively for effect of AngII 
within the group. #,##,### = P<0.05, 0.01, 0.001 respectively for comparison of TG AngII 
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All procedures were performed in accordance with the ‘Guidance on the Operation of the 
Animals’ (Scientific Procedures) Act, 1986 (UK Home Office). Transgenic mice with 
endothelium-targeted overexpression of Nox2 (TG) and global Nox2 knockout mice, both on 
a C57/Bl6 background, were described previously.1,2 Male Nox2 TG were compared with 
matched wild-type littermates (WT). 
 Chimeric mice were generated by bone marrow (BM) transplantation as previously 
described.3 6-8 week old mice received a lethal dose of whole-body irradiation (10Gy, 
15min) and 24 hours later, 0.5x107 BM cells isolated from donor mice were administered by 
tail vein injection. Donor mice were killed by cervical dislocation, their femurs were 
removed aseptically and a single cell suspension was prepared by flushing the marrow 
cavities.  Cells were washed twice in HBSS and resuspended 1x107 cells per ml.   Mice were 
allowed to recover for at least 4 weeks before further study. 
 AngII (1.1mg/kg/day) or saline vehicle was infused via osmotic minipumps (Model 
1002, Alzet, Cupertino, CA) that were implanted subcutaneously under isoflurane 
anesthesia.  Osmotic pumps containing saline were used as controls.  
 Blood pressure was measured either by ambulatory radiotelemetry (PA-C10, Data 
Sciences International) or tail-cuff plethysmography, as described previously.4 Tail-cuff 
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plethysmography was performed after 3 training sessions in conscious restrained mice, 
using a Kent Scientific system (XBP 1000; Torrington, CT). 
 LV pressure-volume relations were measured with a 1.4F micromanometer/ 
microconductance catheter system (SPR-839, Millar Instruments, Houston, TX) introduced 
retrogradely into the LV via the right carotid artery under 2% isoflurane anesthesia.5 Body 
temperature was maintained at 37°C to ensure heart rates of approximately 500 bpm.   
After stabilization, pressure volume loops were obtained via a Aria pressure-volume system 
(Millar,Houston, Tex) coupled to a Powerlab/8SP with Chart Software   (ADinstruments, UK). 
Analysis was conducted using  Chart and pressure volume analysis software (PVAN 3.3 Millar 
Instruments).  The correction factor (alpha) was obtained from the ratio of cardiac output 
obtained from echocardiographic measurements (product of aortic blood flow and aortic 
cross sectional area) and the catheter cardiac output.  Parallel conductance was obtained  
from a series of loops obtained during iv bolus injection of hypertonic saline via the jugular 
vein.  
 Echocardiography was performed under 2% isoflurane anesthesia at heart rates 
>400 bpm, using either a Sonos 5500 system with a 15 MHz linear transducer (Philips, 
Bothell, WA) or a Vevo 2100 with a 30MHz linear array transducer (Visualsonics, Toronto, 
CA). Temperature was maintained at 37°C and heart rates were over 400 bpm. Two-
dimensional and M-mode images were obtained in parasternal long axis and short axis 
views respectively, the latter being measured at the level of the papillary muscles.   
 
Histology and immunohistochemistry.      
Hearts were arrested in diastole by perfusion with 5M KCL at 115 mmHg. Tissue was fixed in 
PFA (1%) and underwent normal histological preparation into paraffin blocks and onto 
slides.  6 µm sections were then deparaffinized and rehydrated through a series of EtOH 
concentrations. Cardiomyocyte area and cardiac fibrosis were quantified in sections stained 
with wheat-germ agglutinin and Picrosirius Red respectively.5 The collagen content was 
quantified as the percentage of total LV area under polarized light. Cardiomyocyte 
membranes and capillaries were co-stained using Wheat Germ Agglutinin (WGA) and 
Isolectin B4, conjugated to TRITC and FITC respectively (Vector RL-1022; Vector, USA).  
Confocal images were obtained on a Leica laser scanning confocal microscope (TCS-SP5) at 
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640x magnification.  The numbers of capillaries per mm2 were calculated from 10 different 
fields (~90 capillaries/field) using AxioVision v4.6 (Carl Zeiss, Germany).  
Cryosections were used for immunostaining with antibodies against CD45 (BD, UK), 
Mac3 (Abcam), CD31/PECAM-1 (Chemicon International), α-SMA (Abcam) and VCAM-1 
(R&D). 4’-6-Diamidino-2-phenylindole (DAPI; Sigma) was used for nuclear staining. Sections 
were then incubated with HRP-labeled secondary antibody and steptavidin-HRP (Perkin 
Elmer) signal amplification was used.  Visualization was conducted by incubation with 
diaminobenzidine (DAKO kit SK4100, Vector Laboratories) followed by Harris 
counterstaining.  CD45 or MAC3-positive cells were counted using semi-automated software 
(AxioVision v4.6, Carl Zeiss, Germany) and expressed as counts per mm2 averaged over 10 
fields.  VCAM-1 positive blood vessels were counted and expressed as % of the total number 
of blood vessels per heart section. 
   
 Leukocyte adhesion assay. 
Coronary microvascular endothelial cells (CMEC) were isolated from hearts of 6-8 week old 
mice and used at passages 2-3.4 A flow chamber (Glycotech, Maryland) was placed onto 
confluent CMEC which had been incubated with or without AngII (0.1µM, 4h). BM cells 
isolated from WT mice and labeled with Celltracker™ (Invitrogen) were added to the 
perfusate which superfused at a rate of 1.5 dynes/cm2 for 30 min.6 Non-bound leukocytes 
were washed away before visualization using an inverted microscope. The number of 
recruited leukocytes was counted in 8-10 fields from 3 separate isolations.   
 
EndMT assays. 
Human aortic endothelial cells (HAEC) were purchased from ATCC and maintained in 
gelatine-coated flasks in medium M199 supplemented with 10% FBS (Invitrogen), 1 ng/ml β-
endothelial cell growth factor (Sigma), 3 μg/ml endothelial cell growth supplement from 
bovine neural tissues (Sigma), 2.5 μg/ml thymidine (Sigma), 10 U/ml heparin (Sigma) and 
100 U/ml penicillin-streptamycin in a 5% CO2 humidified incubator. HAECs were infected 
with Ad.βGal or Ad.Nox2 virus at MOI=20 for 6 hr in the presence of complete growth 
medium, then incubated with human endothelial serum free medium (Invitrogen) in the 
absence or presence of 100 nmol/L AngII. The medium was refreshed every day. 
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Immunofluorescent staining was performed 48 hr post virus infection while Western 
blotting was performed 5 days post infection. 
 Cell slides were fixed with methanol at room temperature for 20min; washed twice 
with PBS, 5min each; permeabilized with 0.01% Triton X-100/PBS for 15 min, and then 
washed with PBS three times for 5min each. Slides were blocked with diluted normal 
donkey serum (1:20 in PBS) at room temperature for 30 min, incubated with rabbit anti-VE-
cadherin (1:100 in diluted donkey serum, 2158, Cell Signaling) and mouse anti-alpha smooth 
muscle actin (1:100 in diluted donkey serum, ab683, Abcam) at 4˚C overnight, followed by 
washing three times with PBS, 10min each. The slides were then incubated with donkey 
anti-Rabbit IgG-Alexa569 (1:1000 in diluted donkey serum, DAKO) and donkey anti-mouse 
IgG-Alexa488 (1:1000 in diluted donkey serum, DAKO) at room temperature for 45 min, 
followed by washing three times with PBS, 10 min each. The slides were counterstained 
with DAPI at room temperature for 5min, followed by washing twice with PBS, 5min each. 
Fluorescent mounting medium and coverslip were applied and images were taken under an 
Olympus 1X81-2 fluorescent microscope with Velocity software by PerkinElmer.  
 
Endothelial cell-fibroblast co-culture 
HAECs were infected with Ad.βGal or Ad.Nox2 virus (MOI=20) as described above for EMT 
assays. 24 hrs post-infection, the HAECs were detached with trypsin and seeded into the 
inserts of 100 mm2 Transwell culture dishes (Sigma) in EC medium. In parallel, human F153 
fibroblasts (ATCC) were seeded in 100 mm2 dishes in F-12/DMEM medium supplemented 
with 10% FBS and 100 U/ml penicillin-streptomycin. Six millilitre human endothelial serum 
free medium (SFM, Life Technologies) with or without 100 nmol/L AngII was added into the 
HAECs-containing inserts and F153-containing dishes, respectively. One HAEC-containing 
insert was put into one F153-containing dish to form a co-culture system. 24 hrs later, the 
cells were collected separately. One third of the F153 cells were used to extract cellular total 
RNA for qPCR analyses with primer sets of 5’-GCTCGTGGAAATGATGGTGC-3’ and 5’-
ACCCTGGGGACCTTCAGAG-3’ for pro-collagen I and 5’-CACAACTGGGACGACATGGAG-3’ and 
5’-TTCATGAGGTAGTCAGTCTGG-3’ for β-actin as loading control. Two-thirds of the cells were 
lysed for Western blot analysis.  
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ROS measurement  
NADPH oxidase activity in homogenised left ventricle (50µg) was assessed by lucigenin (5 
µM)-enhanced chemiluminescence on a plate luminometer (Lucy 1, Rosys Anthos, Wals, 
Austria) as previously described.7   All samples were analyzed in triplicate and the level of 
superoxide production was calculated from the average area under the curve. In some 
experiments, one of the following inhibitors was pre-incubated with the cell homogenate 
for 20 minutes prior to addition of NADPH: the flavoprotein inhibitor, diphenyleneiodonium 
(DPI, 10 µM); a NOS inhibitor, NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME, 100 
µM); a mitochondrial electron transport chain inhibitor, rotenone (50 µM); a superoxide 
scavenger, tiron (10 mM); a putative NADPH oxidase inhibitor, apocynin (10 µM); or a 
xanthine oxidase inhibitor, oxypurinol (100 µM).  




Quantification of mRNA expression was conducted using the Applied Biosystems 7000 
sequence detection system (Applied Biosystems, UK) with SYBR Green and the comparative 
Ct method, with GADPH levels used for normalization. RNA was isolated using an SV total 
RNA isolation kit (Promega, UK) and cDNA synthesised using avian myeloblastosis virus 
reverse transcriptase (AMV; Promega, UK) at 42°C for 90 minutes. Forward and reverse 
primer sequences were as follow (all 5'-3'):   GAPDH: 5’-CGTGCCGCCTGGAGAA, 5’-
CCCTCAGATGCCTGCTTCAC; Actin, 5’-CTGGCACCCAGCACAATG, 5’-
GCCGATCCACACGGAGTACT; Procollagen I, 5’-CCTCAGGGTATTGCTGGACAAC, 5’-
TTGATCCAGAAGGACCTTGTTTG; MCP1, 5’-TGTAGTTTTTGTCACCAAGCTCAAG, 5’-
GTAGGTTCTGATCTCATTTGGTTCC 
Western blot 
Cells (75ml flask) were scratched off in the presence of medium and collected by 
centrifugation at 1000rpm at 4˚C for 5min. The cell pellets were washed twice with ice cold 
PBS and resuspended in 200μl lysis buffer (20mM Tris-Cl, pH7.5, 120mM NaCl, 1mM EDTA, 
1% Triton X-100 plus protease inhibitors) followed by sonication for 6 sec and incubation on 
ice for 45 min. Supernatant was recovered after spinning down at 10,000rpm at 4˚C for 
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5min and protein concentration was detected using Bio-Rad reagents. 25 μg cell lysate was 
applied to SDS-PAGE, followed by transfer to PVDF membrane and incubation with primary 
antibodies against FSP1 (ab41532, Abcam), α-SMA (ab683, Abcam), PECAM-1 (CD31, sc-
1506, Santa Cruz), CD144/ VE-cadherin (Santa Cruz ), Nox2 (BD), GAPDH (sc-25778, Santa 
Cruz) and HRP-conjugated secondary antibody (DAKO). The bound antibodies were revealed 
by ECL reagents (DAKO) and X-ray film.  
Statistics   
Data are expressed as mean±SEM. Comparisons were made by 2-way ANOVA with 
Bonferroni post-hoc testing, 1-way ANOVA or Student’s t-test as appropriate. Analyses were 
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Supplementary Figure 1. Effect of endothelial NOX2 on AngII-induced cardiac hypertrophy 
and fibrosis.   (A) Systolic blood pressure (SBP) after saline or AngII (1.1mg/kg/day) infusion. 
Average SBP ±SEM over a 12-hour dark period (active) is shown. *, P<0.05 AngII vs saline by 
repeated measures ANOVA. n=6/group.  (B) LV NADPH oxidase activity in wild-type and TG 
treated with saline or AngII. (C)  LV/body weight (BW) ratio. (D) Cardiomyocyte area. (E) % 
fibrosis. (F) LV collagen I mRNA levels. * P<0.05, *** P<0.001 by 2-way ANOVA; n=6-
8/group. 
 
Supplementary Figure 2: NADPH-dependent superoxide generation in LV homogenates. 
Lucigenin (5µM)-enhanced chemiluminescence was measured in LV homogenate from WT 
and TG mice with saline or AngII infusion. The chemiluminescence signal was measured over 
15 min in the presence or absence of DPI (10 µM), L-NAME (100 µM), Tiron (20 mM), 
oxypurinol (100 µM), rotenone (100 µM) or apocynin (100 µM). Results were quantified as 
area under the curve and presented as arbitrary integrated light units. Data is shown for the 
effects of inhibitors in the AngII-treated TG group. The inhibitors had similar effects in the 
other 3 groups. **, P<0.01 by 1-way ANOVA followed by Dunnett’s post hoc test, comparing 
to control. n≥6/group. 
 
Supplementary Figure 3: Echocardiographic indices in WT and TG mice treated with AngII 
or saline.  (A) Interventricular septal diameter. (B) LV end diastolic diameter (LVEDD). (C) LV 
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end systolic diameter (LVESD). (D) Ejection fraction. (E) Heart rate (HR). **, P<0.05 by 2-way 
ANOVA. n=12/group. 
 
Supplementary Figure 4. Left ventricular function assessed by pressure-volume analysis. 
(A) Ees, end-systolic elastance. (B) LV dP/dtmax normalized by end-diastolic volume (EDV). (C) 
LV EDV. (D) LV end-systolic volume (ESV). (E) Stroke work (SW). (F) End-diastolic pressure 
volume relation (EDPVR). (G) Representative steady-state pressure-volume loops from wild-
type (WT) and TG mice. (H) Representative pressure-volume loops during acute preload 
reduction in AngII-treated WT and TG. Dashed lines at top left and bottom right of the loops 
show the ESPVR and EDPVR respectively. * P<0.05 AngII vs. respective saline group; # P<0.05 
WT AngII vs. TG AngII by 2-way ANOVA; n=12/group.    
 
Supplementary Figure 5. Inflammatory cell infiltration in vivo. (A,B) Representative 
sections stained for CD45+ and Mac3+ cells, respectively. Scale bars 100 µm. 
 
Supplementary Figure 6: Expression of inflammatory cytokines and pro-fibrotic factors in 
WT and TG heart.  mRNA levels of the genes shown were measured by real-time PCR in LV 
from WT and TG treated with saline or AngII. β-actin levels were used for normalization. 
*P<0.05 compared with respective saline control. n≥6/group. 
 
Supplementary Figure 7: Effects of N-acetyl cysteine (NAC) on blood pressure, cardiac 
hypertrophy and fibrosis.  (A) Systolic blood pressure (SBP) measured by tail cuff 
plethysmography. (B) Cardiac fibrosis in LV sections. (C) LV/BW ratio. (D) CD45+ cells in LV 
sections. NAC (5g/L) was administered in the drinking water for the whole duration of 2 
week AngII infusion.  * P<0.05 vs saline treatment by repeated measure ANOVA. n=6/group 
for BP and morphometric data; n=4/group for histological data.   
 
Supplementary Figure 8: Expression of VCAM-1 in LV sections. Representative examples of 





Supplementary Figure 9: Effects of bone marrow (BM)-derived cells on blood pressure and 
cardiac hypertrophy. Bone marrow chimeric mice were generated as described in the text.   
(A) Superoxide production measured by flow cytometry in dihydroethidine (DHE)-loaded BM 
cells from chimeric mice that previously received bone marrow transfer (BMT) of WT cells 
(left) or Nox2 knockout (KO) cells KO (right). Phorbol ester (PMA) was used to stimulate ROS 
production. (B) Systolic blood pressure (SBP) measured by tail cuff plethysmography in the 
different experimental groups. (C) Cardiac hypertrophy assessed by LV/body weight (BW) 
ratio. *, P<0.05 for the comparisons shown; n=6/group. 
 
Supplementary Figure 10. Effect of NOX2 in bone marrow-derived inflammatory cells on 
AngII-induced fibrosis. (A) Representative Picrosirius Red-stained LV sections. Scale bars 100 
µm.  (B,C) Bottom, mean % fibrosis. See text for details of experimental groups. Horizontal 
lines above the columns in panel B denote significance at P<0.05 level (*) by 1-way ANOVA; 
n≥5/group. 
 
Supplementary Figure 11. Effect of NOX2 on endothelial-mesenchymal transition in 
cultured endothelial cells. (A) Representative confocal images of EC stained for CD144 and 
SMA. Arrow indicates cell expressing both endothelial and mesenchymal markers. (B) 
Representative phase contrast images of EC after AngII treatment. Arrow indicates cell with 
typical elongated fibroblastic phenotype. 
 
Supplementary Figure 12: Effects of endothelial NOX2 overexpression on fibroblasts in 
Transwell co-culture. Endothelial cells were infected with Ad.NOX2 or Ad.β-Gal and 
experiments were performed with or without AngII (100 nmol/L). (A) Fibroblast pro-collagen 
1 mRNA expression levels. (B) Representative Western blots showing markers of 
myofibroblast transformation, smooth muscle actin (SMA) and SM22. (C, D) Mean data for 
experiment shown in panel B. n=4/group. 
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